17-a-methyl-etioallocholan-17b-ol-3-hydroxyimine
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2016 (NCT02731573)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Androgen ReceptorAGONIST
AR agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 17-a-methyl-etioallocholan-17b-ol-3-hydroxyimine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02731573 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2016 | PolyPid Ltd., Tel Aviv University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PolyPid Ltd. | For profit | 1 | 1 | 1 | 2016 |
| Tel Aviv University | Academic/Hospital | 1 | 0 | 1 | 2016 |
2 organizations
Page 1 / 1